Description of Invention: Because psychosis and cognitive decline are among the most common debilitating afflictions of humans, the search for new treatments is very important and timely.
Researchers at the NIH have found that genetic variations on the PIK3CD gene are associated with schizophrenia in Caucasian and African American families and can affect normal human cognition functions such as memory, IQ and executive cognition. The inventors have shown that an inhibitor of the phosphatidylinositol 3-kinase p110 delta (PIK3CD) enzyme, which is encoded by the PIK3CD gene, significantly improves a migratory response that is critically impaired in schizophrenic patients. This drug, as well as other PIK3CD inhibitors, could provide effective treatments of psychosis and cognitive decline.
Applications: Novel target for development of therapeutics of CNS disorders including schizophrenia, psychosis, and cognitive deficiency.
Development Status: Early stage: in vivo rodent and in vitro human cells
Patent Status: HHS, Reference No. E-054-2009/0 PCT, Application No. PCT/US2009/66867 filed 04 Dec 2009 , which published as WO 2010/065923 on 10 Jun 2010
Relevant Publication:
In preparation.
Licensing Status: Available for licensing.
Collaborative Research Opportunity: The National Institute of Mental Health Clinical Brain Disorders Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the development of PIK3CD inhibitors for the treatment of CNS disorders including schizophrenia, psychosis, and cognitive deficiency. Please contact Amanda Law at lawa@mail.nih.gov for more information.
Portfolios: Internal Medicine Internal Medicine - Therapeutics Central Nervous System Central Nervous System - Therapeutics
For Licensing Information Please Contact: Charlene Sydnor Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: sydnorc@mail.nih.gov Phone: 301-435-4689 Fax: 301-402-0220
Description of Invention:
Because psychosis and cognitive decline are among the most common debilitating afflictions of humans, the search for new treatments is very important and timely.
Researchers at the NIH have found that genetic variations on the PIK3CD gene are associated with schizophrenia in Caucasian and African American families and can affect normal human cognition functions such as memory, IQ and executive cognition. The inventors have shown that an inhibitor of the phosphatidylinositol 3-kinase p110 delta (PIK3CD) enzyme, which is encoded by the PIK3CD gene, significantly improves a migratory response that is critically impaired in schizophrenic patients. This drug, as well as other PIK3CD inhibitors, could provide effective treatments of psychosis and cognitive decline.
Applications:
Novel target for development of therapeutics of CNS disorders including schizophrenia, psychosis, and cognitive deficiency.
Development Status:
Early stage: in vivo rodent and in vitro human cells
Inventors:
Amanda J Law (NIMH)
Daniel R Weinberger (NIMH)
Patent Status:
HHS, Reference No. E-054-2009/0
PCT, Application No. PCT/US2009/66867 filed 04 Dec 2009 , which published as WO 2010/065923 on 10 Jun 2010
Relevant Publication:
Licensing Status:
Available for licensing.
Collaborative Research Opportunity:
The National Institute of Mental Health Clinical Brain Disorders Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the development of PIK3CD inhibitors for the treatment of CNS disorders including schizophrenia, psychosis, and cognitive deficiency. Please contact Amanda Law at lawa@mail.nih.gov for more information.
Portfolios:
Internal Medicine
Internal Medicine - Therapeutics
Central Nervous System
Central Nervous System - Therapeutics
For Licensing Information Please Contact:
Charlene Sydnor Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: sydnorc@mail.nih.gov
Phone: 301-435-4689
Fax: 301-402-0220
Ref No: 2148
Updated: 08/2010